Fusion Peptide Improves Stability and Bioactivity of Single Chain Antibody against Rabies Virus
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The combination of rabies immunoglobulin (RIG) with a vaccine is currently effective against rabies infections, but improvements are needed. Genetic engineering antibody technology is an attractive approach for developing novel antibodies to replace RIG. In our previous study, a single-chain variable fragment, scFv57R, against rabies virus glycoprotein was constructed. However, its inherent weak stability and short half-life compared with the parent RIG may limit its diagnostic and therapeutic application. Therefore, an acidic tail of synuclein (ATS) derived from the C-terminal acidic tail of human alpha-synuclein protein was fused to the Cterminus of scFv57R in order to help it resist adverse stress and improve the stability and halflife. The tail showed no apparent effect on the preparation procedure and affinity of the protein, nor did it change the neutralizing potency in vitro. In the ELISA test of molecular stability, the ATS fusion form of the protein, scFv57R-ATS, showed an increase in thermal stability and longer half-life in serum than scFv57R. The protection against fatal rabies virus challenge improved after fusing the tail to the scFv, which may be attributed to the improved stability. Thus, the ATS fusion approach presented here is easily implemented and can be used as a new strategy to improve the stability and half-life of engineered antibody proteins for practical applications.
Abstract
The combination of rabies immunoglobulin (RIG) with a vaccine is currently effective against rabies infections, but improvements are needed. Genetic engineering antibody technology is an attractive approach for developing novel antibodies to replace RIG. In our previous study, a single-chain variable fragment, scFv57R, against rabies virus glycoprotein was constructed. However, its inherent weak stability and short half-life compared with the parent RIG may limit its diagnostic and therapeutic application. Therefore, an acidic tail of synuclein (ATS) derived from the C-terminal acidic tail of human alpha-synuclein protein was fused to the Cterminus of scFv57R in order to help it resist adverse stress and improve the stability and halflife. The tail showed no apparent effect on the preparation procedure and affinity of the protein, nor did it change the neutralizing potency in vitro. In the ELISA test of molecular stability, the ATS fusion form of the protein, scFv57R-ATS, showed an increase in thermal stability and longer half-life in serum than scFv57R. The protection against fatal rabies virus challenge improved after fusing the tail to the scFv, which may be attributed to the improved stability. Thus, the ATS fusion approach presented here is easily implemented and can be used as a new strategy to improve the stability and half-life of engineered antibody proteins for practical applications.
참고문헌 (30)
- Nagarajan T, "Monoclonal antibodies for the prevention of rabies: theory and clinical practice", Antibody Technol. J, 4, pp.1~12 (2014)
- Bourhy H, "Rabies, still neglected after 125 years of vaccination", PLoS Negl. Trop. Dis, 4, pp.e839~e839 (2010)
- Knobel DL, "Re-evaluating the burden of rabies in Africa and Asia", Bull. World Health Organ, 83, pp.360~368 (2005)
- Jaap G, "Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin", J. Infect. Dis, 193, pp.796~801 (2006)
- Richard F, "Current and future tools for global canine rabies elimination", Antiviral Res, 100, pp.220~225 (2013)
- Nelson AL, "Antibody fragments: hope and hype", MAbs, 2, pp.77~83 (2010)
- Bird RE, "Single-chain antigen-binding proteins", Science, 242, pp.423~426 (1988)
- Weisser NE, "Applications of single-chain variable fragment antibodies in therapeutics and diagnostics", Biotechnol. Adv, 27, pp.502~520 (2009)
- Cheng Y, "A VL-linker-VH orientation dependent single chain variable antibody fragment against rabies virus G protein with enhanced neutralizing potency in vivo", Protein Pept. Lett, 23, pp.24~32 (2015)
- Bakker A, "First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity", Vaccine, 26, pp.5922~5927 (2008)
- Myun PS, "Effects of novel peptides derived from the acidic tail of synuclein (ATS) on the aggregation and stability of fusion proteins", Protein Eng. Des. Sel, 17, pp.251~260 (2004)
- Lee EN, "Stabilizing peptide fusion for solving the stability and solubility problems of therapeutic proteins", Pharm. Res, 22, pp.1735~1746 (2005)
- Goldman ER, "Negative tail fusions can improve ruggedness of single domain antibodies", Protein Expr. Purif, 95, pp.226~232 (2014)
- Duan Y, "A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency", Mol. Immunol, 51, pp.188~196 (2012)
- Yuan R, "Preparation and diagnostic use of a novel recombinant single-chain antibody against rabies virus glycoprotein", Appl. Microbiol. Biotechnol, 98, pp.1547~1555 (2014)
- Wu X, "Affinity maturation of a human single-chain Fv by phage display", Chinese J. Microbiol. Immunol, 21, pp.156~159 (2001)
- Reed LJ, "A simple method of estimating fifty per cent endpoints", Am. J. Hyg, 27, pp.493~497 (1938)
- Duan Y, "Negative effects of a disulfide bond mismatch in anti-rabies G protein single-chain antibody variable fragment FV57", Mol. Immunol, 59, pp.136~141 (2014)
- Safar F, "Development trends for generation of single-chain antibody fragments", Immunopharmacol. Immunotoxicol, 36, pp.1~12 (2014)
- Cai K, "Novel human 3-domain disulfide-stabilized antibody fragment against glycoprotein of rabies virus", Microb. Infect, 10, pp.548~555 (2008)
- Wang DD, "Expression, purification and characterization of a human single-chain Fv antibody fragment fused with the Fc of an IgG1 targeting a rabies antigen in Pichia pastoris", Protein Expr. Purif, 86, pp.75~81 (2012)
- Liu X, "Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine", PLoS One, 6, pp.e19848~ (2011)
- Jiang H, "Purification of clinical-grade disulfide stabilized antibody fragment variable-Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli", Appl. Microbiol. Biotechnol, 97, pp.621~632 (2013)
- Lee JH, "Intracellular reprogramming of expression, glycosylation, and function of a plant-derived antiviral therapeutic monoclonal antibody", PLoS One, 8, pp.e68772~ (2013)
- Kim Y, "Expression of human interferon alpha-1 with enhanced stability via the tagging system of a stabilizing peptide", Protein Expr. Purif, 63, pp.140~146 (2009)
- Both L, "Passive immunity in the prevention of rabies", Lancet Infect. Dis, 12, pp.397~407 (2012)
- Koprowski H, "Use of hyperimmune antirabies serum concentrates in experimental rabies", Am. J. Med, 8, pp.412~420 (1950)
- Sikes RK, "Effective protection of monkeys against death from street virus by post-exposure administration of tissueculture rabies vaccine", Bull. World Health Organ, 45, pp.1~11 (1971)
- Turki I, "Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency", Mol. Immunol, 57, pp.66~73 (2014)
- Todorovska A, "Design and application of diabodies, triabodies and tetrabodies for cancer targeting", J. Immunol. Methods, 248, pp.47~66 (2001)